Correlation of changes in patient-reported quality of life with physician-rated global impression of change in patients with narcolepsy participating in a clinical trial of sodium oxybate : a post hoc analysis by Bogan, Richard et al.
This article has been published in a revised form in Neurology and Therapy [DOI 10.1007/s40120-017-
0076-6]. This version is free to view and download for private research and study only. © Neurology and
Therapy.
ORIGINAL RESEARCH
Correlation of Changes in Patient-Reported Quality
of Life With Physician-Rated Global Impression
of Change in Patients With Narcolepsy Participating
in a Clinical Trial of Sodium Oxybate: A Post Hoc
Analysis
Richard K. Bogan . Jed Black . Todd Swick . Mortimer Mamelak .
Ruzica Kovacevic-Ristanovic . Kathleen F. Villa . Fannie Mori .
Jacques Montplaisir
Received: April 20, 2017 / Published online: July 13, 2017
 The Author(s) 2017. This article is an open access publication
ABSTRACT
Introduction: Narcolepsy patients report lower
health-related quality of life (HRQoL) than the
general population, as measured by the Short
Form-36 Health Survey (SF-36). This analysis
evaluated whether changes in SF-36 correlated
with physician-rated Clinical Global Impression
of Change (CGI-C).
Methods: Data were from 209 of 228 nar-
colepsy patients participating in an 8-week
clinical trial of sodium oxybate. Changes from
baseline for SF-36 subscales (Physical Function-
ing, Role Physical, Bodily Pain, General Health,
Vitality, Social Functioning, Role Emotional,
and Mental Health) and the summary scores
were evaluated for correlation with CGI-C
overall and by treatment group. Correlations
were calculated using the Pearson product-mo-
ment correlation coefficient (r).
Results: Correlations described an inverse rela-
tionship in scores, but a direct relationship in
improvement; lower CGI-C scores (i.e., better)
were associated with higher SF-36 subscale
scores (i.e., improved HRQoL). Moderate and
significant correlations were observed for Vital-
ity (r = -0.464; P\0.0001) and Role Physical
(r = -0.310; P\0.0001) subscales, but weak
correlations were observed with other subscales
including summary scores. Correlations were
stronger at higher sodium oxybate doses for
most SF-36 subscales.
Conclusion: Some aspects of HRQoL, measured
by the SF-36, may be associated with nar-
colepsy. In particular, Vitality (indicative of
energy and tiredness) and Role Physical (impact
of physical function on daily roles) moderately
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Montréal, QC, Canada
Neurol Ther (2017) 6:237–245
DOI 10.1007/s40120-017-0076-6
correlated with overall change in status
observed by clinicians. However, lack of strong
correlations between SF-36 and CGI-C indicates
differences in patient and clinician perspectives
of disease, and suggest a need for broader
assessment of the impact of narcolepsy and its
treatment on patients.
Funding: Jazz Pharmaceuticals.
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INTRODUCTION
Narcolepsy, a chronic neurologic disease with
no known cure, is associated with an economic
burden resulting from higher healthcare
resource utilization and reduced productivity
relative to those without narcolepsy, and a
humanistic burden, since patients with nar-
colepsy report substantially impaired
health-related quality of life (HRQoL) [1–4].
Studies that have used the 36-item Short Form
Health Status survey (SF-36) [5], which is a
generic patient-reported measure of HRQoL,
have consistently shown lower scores on most
SF-36 subscales in narcolepsy patients not only
compared with the general population, but also
relative to patients with other chronic condi-
tions including obstructive sleep apnea,
Parkinson’s disease, and epilepsy [6–15]. In
particular, of the eight SF-36 subscales, the
greatest differences between narcolepsy patients
and the general population have been for the
subscales of Vitality and Role Physical; the eight
subscales of the SF-36 are Physical Function (PF;
ability to perform physical activity), Role Phys-
ical (RP; assesses the impact of physical function
on daily roles including work and daily activi-
ties), Bodily Pain (BP; presence of pain and its
impact on limiting activities), General Health
(GH; overall health status), Vitality (VT; energy
and tiredness), Social Function (SF; ability to
perform social activities), Role Emotional (RE;
impact of emotional problems on participation
in life activities such as work and other daily
activities), and Mental Health (MH; general
mood, i.e., anxiety, depression).
Clinical change in disease status is often
assessed using a generic global measure, the
Clinical Global Impression of Change (CGI-C)
[16], which is a frequently used summary scale
from the clinician’s perspective. The CGI-C
asks the clinician to rate on a scale from 1
(=very much improved to 7 (=very much
worse) how much the patient has improved
from their perspective since baseline or an
earlier assessment. An analysis of SF-36 data
from a clinical trial of sodium oxybate (SXB)
suggested dose-dependent effects of SXB on the
SF-36, with significant improvements for the
change from baseline relative to placebo with
the 9 g/night dose on the SF-36 domains of VT,
GH, PF, and SF, as well as the Physical Com-
ponent Summary (PCS) [17]. Similarly, analysis
of data from this clinical trial showed that the
proportion of patients in each SXB treatment
group who were rated as Much Improved/Very
Much Improved by the investigator was sig-
nificantly greater than placebo [18]. However,
it is not clear if the clinician’s assessment using
this scale accurately reflects what the patient
may be experiencing with regard to the broader
impact of narcolepsy on health status or
HRQoL.
Patient-reported outcomes are becoming
increasingly important to researchers and reg-
ulatory agencies, including the United States
Food and Drug Administration [19]. This
importance suggests not only that there is a
need for evaluating changes in disease status
from both the clinical and patient perspectives,
but also a need to understand the similarities
and differences in how clinicians and patients
perceive and interpret the impact of changes in
disease. Furthermore, it is useful to identify
whether any of the SF-36 domains reflect nar-
colepsy-specific issues or correlate with the
clinician’s perspective of a patient’s improve-
ment or worsening. Therefore, the purpose of
this analysis was to provide initial assessment of
the degree of correlation between these out-
comes using data from the previously men-
tioned clinical trial of SXB that included both
the SF-36 and the CGI-C [17, 18, 20]; SXB is
approved for the treatment of both excessive
daytime sleepiness and cataplexy in patients
with narcolepsy [21].
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METHODS
Study Design and Population
This post hoc analysis was based on data from
an 8-week clinical trial of SXB for which the
methodology and results have previously been
published [18]. Patients were required to be
C16 years of age and have a diagnosis of nar-
colepsy with cataplexy based on clinical history,
an overnight polysomnogram, and a multiple
sleep latency test. Randomization was to treat-
ment with placebo or SXB 4.5 g, 6 g, or 9 g
administered as two equally divided nightly
doses. This article does not contain any new
studies with human or animal subjects per-
formed by any of the authors.
Outcomes
Both the CGI-C [16] and the SF-36 [5] were
included as outcomes in the trial, with the for-
mer assessed at Week 8, and the latter as an
exploratory efficacy endpoint at baseline, Week
4, and Week 8. The CGI-C was scored by the
clinician from 1 = very much improved to
7 = very much worse. Scores on the SF-36 range
from 0 to 100, with higher scores indicating
better HRQoL. In addition to the eight sub-
scales, the SF-36 derives two summary scales
from positively weighting specific domains; the
PCS, which is derived from weighting the
domains of PF, RP, BP, and GH, and the Mental
Component Summary (MCS), derived from
weighting the domains of VT, SF, RE, and MH.
Statistical Analysis
This analysis was based on data that were
available for 209 of the 228 patients in the
intent-to-treat population of the study; 19
patients did not have both CGI-C and SF-36
results for inclusion in the correlation analysis.
Missing Week 8 values on the SF-36 were
imputed using the last observation (Week 4
values) carried forward. Regardless of treatment
group, the change from baseline at Week 8 for
all SF-36 subscales and the two summary scores
were evaluated for correlation with the CGI-C at
Week 8 using the Pearson product-moment
coefficient (r), such that H0: q = 0, where abso-
lute values of r B 0.30 represent a weak correla-
tion, 0.30–0.50 are moderate, and C0.50 are
strong [22]. Scatterplots and regression lines
were developed to visualize the relationship
between SF-36 and CGI-C. These scatterplot
analyses estimated both the 95% confidence
interval of the regression, as well as the 95%
prediction limits, which indicate the predictive
probability that future observations will fall
within these boundaries. Additionally, Pearson
correlation analysis was performed to determine
the relationships between the CGI-C at Week 8




Treatment groups were generally well-balanced
for demographic characteristics, and the popu-
lation was predominantly female (65.4%),
white (86.0%), with a mean (SD) age of 40.5
(15.3) years. Baseline scores on the SF-36 were
also well-balanced among the treatment groups
(Table 1).
Correlation Between CGI-C and SF-36
Regardless of Treatment Group
A general relationship was observed between
scores on the CGI-C and SF-36, and this rela-
tionship was inverse as indicated by the nega-
tive correlation coefficients, such that CGI-C
scores indicating greater improvement (i.e.,
lower scores) were associated with improved
HRQoL with SF-36 domain scores (i.e., higher
SF-36 scores) (Table 2). The correlations were
moderate and significant for the subscales of VT
(r = -0.464; P\0.0001) and RP (r = -0.310;
P\0.0001). However, all other correlations
were weak including those for PCS and MCS,
although the correlations were significant
except for the two subscales with the weakest
correlations, BP and RE (Table 2).
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Scatterplots of the relationship between
CGI-C and the two SF-36 subscales that had
moderate correlations, VT (Fig. 1a) and RP
(Fig. 1b), show low R2 values for the linear
regression of both subscales, 0.215 and 0.096 for
VT and RP, respectively, and wide 95% predic-
tion limits, providing further visual representa-
tion that the correlations are not strong. For the
other SF-36 subscales, the R2 values of the linear
regression ranged from 0.0079 (RE) to 0.0834
(SF) with similarly wide 95% prediction limits
(data not shown).
Correlation Between CGI-C and SF-36
by Treatment Group
Correlations appeared to be dose dependent
across SXB doses for PF, RP, VT, SF, and the PCS,
with the SXB 9 g dose showing strong correla-
tions for these subscales except SF for which the













Male 17 (28.8) 21 (32.8) 22 (37.9) 19 (40.4) 79 (34.6)
Female 42 (71.2) 43 (67.2) 36 (62.1) 28 (59.6) 149 (65.4)
Age, years, mean (SD) 40.8 (15.5) 41.8 (16.7) 39.2 (15.9) 39.9 (12.5) 40.5 (15.3)
Race, n (%)
White 54 (91.5) 50 (78.1) 49 (84.5) 43 (91.5) 196 (86.0)
Black 3 (5.1) 11 (17.2) 7 (12.1) 4 (8.5) 25 (11.0)
Other 2 (3.4) 3 (4.7) 2 (3.4) 0 7 (3.0)
SF-36 score, mean (SD)
Physical functioning 44.5 (9.9)b 45.9 (10.8) 46.1 (8.0) 43.6 (10.9) 45.1 (9.9)
Role physical 34.7 (9.4)b 38.0 (11.4) 37.8 (11.1) 35.3 (11.3) 36.6 (10.9)
Bodily pain 47.8 (10.6)b 50.6 (10.3) 50.9 (10.0) 49.3 (10.1) 49.7 (10.3)
General health 43.0 (9.1)b 47.5 (10.0) 45.1 (11.4) 45.0 (9.7) 45.2 (10.2)
Vitality 37.4 (8.9)b 38.9 (10.8) 37.7 (8.9) 36.6 (10.6) 37.8 (9.8)
Social functioning 34.3 (13.2)b 38.1 (12.8) 37.1 (11.7) 33.6 (13.9) 35.9 (12.9)
Role emotional 40.8 (13.4)b 45.8 (12.3) 39.9 (13.1) 41.7 (13.9) 42.2 (13.2)
Mental health 46.2 (9.2)b 45.7 (11.6) 43.5 (10.2) 46.6 (10.5) 45.5 (10.4)
Physical component
summary
42.2 (8.3)b 45.1 (8.5) 46.3 (9.0) 42.7 (8.9) 44.2 (8.8)
Mental component
summary
40.5 (10.6)b 42.7 (12.0) 38.5 (10.2) 40.6 (11.3) 40.6 (11.1)
a Intent-to-treat population was defined as all patients who received at least one dose of double-blind medication and had
efficacy data at baseline and Visits 6 (end of titration period) and/or 7 (end of treatment)
b n = 58
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correlation was moderate (Table 3); the stron-
gest correlation was for VT with SXB 9 g. Cor-
relations were generally weak or moderate for
the other subscales across all doses, consistent
with overall results.
DISCUSSION
Determining how global changes in disease and
their impact are assessed and identifying con-
cordance or discordance between clinician and
patient perspectives can contribute to under-
standing what is considered an effective treat-
ment. Correlation analyses such as those
presented here help enhance this understand-
ing by validating patient experiences as well as
clinician observations.
While this analysis showed that most of the
SF-36 subscales only weakly correlated with the
CGI-C, it did identify two subscales with mod-
erate correlations suggestive of changes in
patient-reported domains that may be perceived
by clinicians and likely enable them to deter-
mine patient improvement. These subscales, VT
and RP, are also the subscales that are most
frequently reported to have the lowest value
(poorest outcome) among the SF-36 domains in
patients with narcolepsy as well as the greatest
difference in scores between narcolepsy patients
and the general population [6–8]. In particular,
VT can be interpreted as a measure of fatigue,
which is frequently reported by patients with
narcolepsy [26, 27]. In contrast, the low corre-
lation coefficients and the lack of statistical
significance in two other SF-36 subscales indi-
cate domains where there either was not a good
match between patient and clinician perspec-
tives (RE) or did not adequately reflect dis-
ease-specific issues of patients with narcolepsy
(BP). The correlation coefficients for PF, GH, SF,
and MH as well as the PCS and MCS also suggest
that despite showing statistical significance,
these subscales may not be adequate as indica-
tors of change in narcolepsy. Based on these
results, it may be prudent to suggest that while
the SF-36 can provide a general assessment of
HRQoL in patients with narcolepsy, the use of
other, more appropriate measures should be
considered for evaluating global and dis-
ease-specific changes.
However, the low to moderate correlations
also indicate lack of agreement, at least in part,
between how clinicians and patients perceive
improvements. This lack of agreement is con-
sistent with the discordance between patient
and clinician perspectives of global assessments
of disease activity and treatment response that
has also been reported in other diseases [23–25]
suggesting that the variables contributing to a
patient’s perception of disease may be different
from that of the healthcare provider. Such a lack
of agreement, especially with regard to the low
correlations observed for mental health in the
current analysis, further supports the need for
narcolepsy assessment that incorporates a
broader range of patient-reported outcomes
that more closely align with patient perceptions
of treatment effects.
Limitations
A limitation of this study is that it was a post
hoc analysis, although data were available
from most of the patients in the study. Addi-
tionally, the 8-week duration of the study may
also be considered a limitation because it may
Table 2 Correlation of physician-rated Clinical Global
Impression of Change (CGI-C) at Week 8 with changes
reported by patients on the 36-item Short Form Health
Survey (SF-36) regardless of treatment (n = 209)
SF-36 domain Pearson r P value
Physical functioning -0.196 \0.05
Role physical -0.310 \0.0001
Bodily pain -0.120 0.0834
General health -0.155 \0.05
Vitality -0.464 \0.0001
Social functioning -0.289 \0.0001
Role emotional -0.089 0.201
Mental health -0.182 \0.05
Physical component summary -0.286 \0.0001
Mental component summary -0.229 \0.05
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have been too short to capture patient-re-
ported changes in HRQoL; response onset,
assessed as clinically meaningful improve-
ments in EDS and cataplexy, were observed in
most patients within 2 months, but a longer
period was needed to achieve maximum
response [28]. Finally, the study could also
potentially be criticized for not evaluating
factors that may confound the relationship.
However, it should be noted that these corre-
lations reflect within-subject assessments,
since patient scores from both outcome mea-
sures were assessed within the same patient
among those who had available data or who
met the imputation guidelines.
CONCLUSION
Only two SF-36 subscales showed moderate
correlation with overall change in status
observed by clinicians, VT and RP, suggesting
that improvement in these domains may be
reflected by clinicians’ ratings. However, other
SF-36 subscales as well as the summary scores
expressed only a weak correlation with clinician
ratings, indicating that some aspects of HRQoL
measured by the SF-36 may assess symptoms of
narcolepsy that are also recognized by physi-
cians. However, there is also discordance
between patient and physician perspectives of
disease, further suggesting a need for a broader
Fig. 1 Scatterplot showing moderate correlation at Week 8 between Clinical Global Impression of Change (CGI-C) and
the 36-item Short Form Health Status survey (SF-36) subscales of a vitality and b role physical
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assessment of narcolepsy and treatment effects
that emphasizes the patient perspective.
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